Display options
Cite
Birse CE, Lagier RJ, FitzHugh W, et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015;12(1):18doi: 10.1186/s12014-015-9090-9.
Birse, C. E., Lagier, R. J., FitzHugh, W., Pass, H. I., Rom, W. N., Edell, E. S., Bungum, A. O., Maldonado, F., Jett, J. R., Mesri, M., Sult, E., Joseloff, E., Li, A., Heidbrink, J., Dhariwal, G., Danis, C., Tomic, J. L., Bruce, R. J., Moore, P. A., He, T., Lewis, M. E., & Ruben, S. M. (2015). Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clinical proteomics, 12(1), 18. https://doi.org/10.1186/s12014-015-9090-9
Birse, Charles E, et al. "Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium." Clinical proteomics vol. 12,1 (2015): 18. doi: https://doi.org/10.1186/s12014-015-9090-9
Birse CE, Lagier RJ, FitzHugh W, Pass HI, Rom WN, Edell ES, Bungum AO, Maldonado F, Jett JR, Mesri M, Sult E, Joseloff E, Li A, Heidbrink J, Dhariwal G, Danis C, Tomic JL, Bruce RJ, Moore PA, He T, Lewis ME, Ruben SM. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics. 2015 Jul 16;12(1):18. doi: 10.1186/s12014-015-9090-9. eCollection 2015. PMID: 26279647; PMCID: PMC4537594.
Copy Download .nbib Format: NLM
Share it on

Clin Proteomics. 2015 Jul 16;12(1):18. doi: 10.1186/s12014-015-9090-9. eCollection 2015.

Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium.

Clinical proteomics

Charles E Birse, Robert J Lagier, William FitzHugh, Harvey I Pass, William N Rom, Eric S Edell, Aaron O Bungum, Fabien Maldonado, James R Jett, Mehdi Mesri, Erin Sult, Elizabeth Joseloff, Aiqun Li, Jenny Heidbrink, Gulshan Dhariwal, Chad Danis, Jennifer L Tomic, Robert J Bruce, Paul A Moore, Tao He, Marcia E Lewis, Steve M Ruben

Affiliations

  1. Celera employees during the course of these studies, Celera, 1311 Harbor Bay Parkway, Alameda, CA 94502 USA.
  2. Department of Cardiothoracic Surgery, NYU Langone Medical Center, 530 First Avenue, New York, NY USA.
  3. Division of Pulmonary, Critical Care, and Sleep Medicine, NYU School of Medicine, New York, NY USA.
  4. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN USA.
  5. Division of Oncology, National Jewish Health, Denver, CO USA.

PMID: 26279647 PMCID: PMC4537594 DOI: 10.1186/s12014-015-9090-9

Abstract

BACKGROUND: Support for early detection of lung cancer has emerged from the National Lung Screening Trial (NLST), in which low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20 % relative to chest x-ray. The US Preventive Services Task Force (USPSTF) recently recommended annual screening for the high-risk population, concluding that the benefits (life years gained) outweighed harms (false positive findings, abortive biopsy/surgery, radiation exposure). In making their recommendation, the USPSTF noted that the moderate net benefit of screening was dependent on the resolution of most false-positive results without invasive procedures. Circulating biomarkers may serve as a valuable adjunctive tool to imaging.

RESULTS: We developed a broad-based proteomics discovery program, integrating liquid chromatography/mass spectrometry (LC/MS) analyses of freshly resected lung tumor specimens (n = 13), lung cancer cell lines (n = 17), and conditioned media collected from tumor cell lines (n = 7). To enrich for biomarkers likely to be found at elevated levels in the peripheral circulation of lung cancer patients, proteins were prioritized based on predicted subcellular localization (secreted, cell-membrane associated) and differential expression in disease samples. 179 candidate biomarkers were identified. Several markers selected for further validation showed elevated levels in serum collected from subjects with stage I NSCLC (n = 94), relative to healthy smoker controls (n = 189). An 8-marker model was developed (TFPI, MDK, OPN, MMP2, TIMP1, CEA, CYFRA 21-1, SCC) which accurately distinguished subjects with lung cancer (n = 50) from high risk smokers (n = 50) in an independent validation study (AUC = 0.775).

CONCLUSIONS: Integrating biomarker discovery from multiple sample types (fresh tissue, cell lines and conditioned medium) has resulted in a diverse repertoire of candidate biomarkers. This unique collection of biomarkers may have clinical utility in lung cancer detection and diagnoses.

Keywords: Biomarker; Discovery; Early detection; Lung cancer; Mass spectrometry; Proteomics

References

  1. Anticancer Res. 2011 Nov;31(11):4031-8 - PubMed
  2. J Immunol Methods. 2002 Dec 15;270(2):227-33 - PubMed
  3. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3128-35 - PubMed
  4. Radiology. 2003 Mar;226(3):756-61 - PubMed
  5. J Proteome Res. 2005 Jul-Aug;4(4):1274-86 - PubMed
  6. J Clin Oncol. 2007 Dec 10;25(35):5578-83 - PubMed
  7. J Clin Oncol. 2009 Jun 10;27(17):2787-92 - PubMed
  8. Proteomics. 2003 Sep;3(9):1720-4 - PubMed
  9. Anal Chem. 2007 Aug 1;79(15):5651-8 - PubMed
  10. J Pathol. 2007 Jun;212(2):152-60 - PubMed
  11. Proteomics Clin Appl. 2014 Apr;8(3-4):251-7 - PubMed
  12. Ann Immunol (Paris). 1983 Nov-Dec;134D(3):319-31 - PubMed
  13. Cancer Lett. 2006 Feb 20;233(1):16-20 - PubMed
  14. J Thorac Oncol. 2012 Apr;7(4):698-708 - PubMed
  15. Nucleic Acids Res. 2013 Jan;41(Database issue):D377-86 - PubMed
  16. Ann Intern Med. 2013 Sep 17;159(6):411-20 - PubMed
  17. J Biol Chem. 2003 Oct 10;278(41):40364-72 - PubMed
  18. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1633-43 - PubMed
  19. J Thorac Oncol. 2011 Apr;6(4):725-34 - PubMed
  20. Proteomics. 2015 Jan;15(1):58-67 - PubMed
  21. Adv Intern Med. 1974;19:413-33 - PubMed
  22. Biochem Biophys Res Commun. 2015 Feb 6;457(2):177-82 - PubMed
  23. Nucleic Acids Res. 2014 Jan;42(Database issue):D959-65 - PubMed
  24. PLoS One. 2013 Nov 13;8(11):e78885 - PubMed
  25. Cancer Cell. 2011 Sep 13;20(3):289-99 - PubMed
  26. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82 - PubMed
  27. J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93 - PubMed
  28. J Proteomics. 2013 Aug 26;89:227-37 - PubMed
  29. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1751 - PubMed
  30. Ann Intern Med. 2014 Mar 4;160(5):330-8 - PubMed
  31. Br J Cancer. 2000 Sep;83(6):701-6 - PubMed
  32. Tumour Biol. 2013 Oct;34(5):2995-3002 - PubMed
  33. FEBS Lett. 1992 Feb 17;298(1):29-32 - PubMed
  34. Cell. 1989 Apr 21;57(2):327-34 - PubMed
  35. Lung Cancer. 2006 Oct;54(1):87-94 - PubMed
  36. Mol Cell Proteomics. 2002 Nov;1(11):845-67 - PubMed
  37. Clin Lung Cancer. 2014 Sep;15(5):372-8.e1 - PubMed
  38. Adv Carbohydr Chem. 1956;48(11):1-41 - PubMed
  39. J Proteome Res. 2010 Dec 3;9(12):6440-9 - PubMed
  40. Cancer Prev Res (Phila). 2012 Aug;5(8):992-1006 - PubMed
  41. Sci Transl Med. 2013 Oct 16;5(207):207ra142 - PubMed
  42. Clin Proteomics. 2014 Aug 01;11(1):32 - PubMed
  43. N Engl J Med. 2013 May 23;368(21):1980-91 - PubMed
  44. J Pathol. 2006 Feb;208(3):327-39 - PubMed
  45. Oncogene. 2008 Jun 12;27(26):3721-8 - PubMed
  46. Nat Protoc. 2013 Aug;8(8):1551-66 - PubMed
  47. Cancer. 2000 Oct 1;89(7):1448-56 - PubMed
  48. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5609-13 - PubMed
  49. PLoS One. 2010 Dec 07;5(12):e15003 - PubMed
  50. Anticancer Res. 2004 Jan-Feb;24(1):241-7 - PubMed
  51. Biochem Pharmacol. 1995 Sep 28;50(7):959-66 - PubMed
  52. Respir Med. 2004 Feb;98(2):173-7 - PubMed
  53. N Engl J Med. 2011 Aug 4;365(5):395-409 - PubMed
  54. Cancer Res. 1991 Sep 15;51(18):5003-5 - PubMed
  55. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  56. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):786-92 - PubMed
  57. Mol Cell Proteomics. 2009 Dec;8(12 ):2746-58 - PubMed
  58. Oncol Rep. 2013 Feb;29(2):469-73 - PubMed
  59. Clin Lung Cancer. 2008 Mar;9(2):112-5 - PubMed
  60. J Thorac Oncol. 2013 Jan;8(1):31-6 - PubMed
  61. J Thorac Oncol. 2007 Oct;2(10):893-901 - PubMed
  62. Oncogene. 2000 Dec 27;19(56):6642-50 - PubMed
  63. Nat Biotechnol. 2003 Jun;21(6):660-6 - PubMed
  64. Anticancer Agents Med Chem. 2012 Sep;12(7):744-52 - PubMed
  65. Cancer Sci. 2008 May;99(5):849-55 - PubMed
  66. Cancer Res. 1988 Apr 1;48(7):1904-9 - PubMed
  67. Cancer Res. 1997 May 1;57(9):1814-9 - PubMed
  68. Cancer Genomics Proteomics. 2015 Jan-Feb;12(1):39-48 - PubMed
  69. Nucleic Acids Res. 2014 Jan;42(Database issue):D191-8 - PubMed
  70. Ann N Y Acad Sci. 2004 Dec;1028:380-9 - PubMed
  71. Mol Cell Proteomics. 2005 Oct;4(10):1480-6 - PubMed

Publication Types

Grant support